Explore the intersection of psychedelic medicine and cultural values, diving into ethical considerations and societal impacts within this transformative field.
Navigate the complex legal and political landscape surrounding psychedelic medicine, including regulatory updates, policy changes, and advocacy efforts.
Delve into cutting-edge scientific research and breakthroughs in the field of psychedelic medicine, with a focus on understanding the mechanisms, efficacy, and safety of these substances.
Delve into the captivating world of psychedelic medicine at Wonderland, where the frontiers of science, spirituality, and wellness converge to create an experience unlike any other.
Discover the keys to living longer while exploring the potential of humanity’s future. Wonderland brings together the latest groundbreaking research, charting trends, and investment opportunities for an experience of a lifetime.
Uncover state-of-the-art technology, evolving trends, insightful marketing strategies, and valuable opportunities designed for professionals in the mental health and brain care sector.
With this year’s Wonderland, we want to expand the conversation to take a deep dive into the intersection of these fields with psychedelic medicine, and how combining all three can lead to living not only a longer, but happier life.
The premier global conference, Wonderland is a groundbreaking event experience where visionaries and pioneers unite to explore the future of psychedelic medicine, the business of mental health and the future of longevity medicine.
Are you ready to share your passion, knowledge, and insights with a global audience of executives, researchers, and practitioners? This is your opportunity to contribute to the evolving conversation on the future of medicine showcase your unique expertise, and inspire change in the world.
Wonderland presents a one-of-a-kind opportunity for businesses and organizations to exhibit their cutting-edge products, services, and visionary solutions to a captivated audience of professionals in the mental health and psychedelic medicine fields.
We invite companies with a shared vision to submit partnership proposals and collaborate with us on this extraordinary event. By joining forces, we can create a truly unique experience for attendees, foster lasting connections, and drive the future of psychedelic healing together.
Elevate your brand’s presence in the psychedelic medicine industry with our comprehensive suite of services, tailored to captivate your audience, strengthen your market position, and foster meaningful connections within the community.
Our advertising options give you the ability to target users on their desktops, mobile devices, or when they’re at one of our in-person events. You decide when and where to connect with our audience.
Our dedicated team provides passion and specialist insight across a variety of sectors and services so, whatever the challenge, the impact is guaranteed.
You’re doing the hard work of changing the world, let our team of internationally award-winning creators focus on spreading the word as far as possible and telling your story to the world.
Microdose’s events and conferences are bringing psychedelic medicine to the mainstream. Top investors, business leaders, researchers, and advocates — our events are the hub for the psychedelic renaissance.
Justin Hanka
MindBio Therapeutics
The team at Microdose are leaders in public relations activities and have successfully assisted MindBio Therapeutics to reach a global audience that we would not have been able to reach without them.
Natalie Dolphin
Wellbeing Digital Science
The Microdose team worked with us, identifying key activities we were undertaking and promoting them through its wide-ranging media connections within psychedelics, cannabis and biotech publications. The Microdose team is professional and passionate about what it does, and this was reinforced during the pandemic when it went above and beyond our agreed contract, working with us to get key messages out to the industry quickly and effectively.
Microdose X is shifting the world’s perception of psychedelic medicine, one city at a time. Join the world’s fastest-growing psychedelic network and enjoy vibrant local meetups with like-minded souls.
The Science of Psychedelics is an accredited, definitive guide to the clinical applications of entheogenic medicines, and offers a solid introduction to psychedelic-assisted therapy and “trip sitting” skills to physicians, psychologists, social workers, mental health counselors, pharmacists, and other empowered individuals. Become trained in psychedelic medicines like psilocybin, LSD, MDMA, and ketamine today.
Psychedelia is a quarterly publication examining the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. From psilocybin mushrooms to LSD to DMT, psychedelics have the potential to revolutionize mental healthcare in North America. Psychedelia will detail the journey towards acceptance of psychedelic-assisted therapies.
Microdose is a small team of people who want to help share the potential of psychedelic medicine with the world, bringing together our unique expertise and diverse backgrounds to create a platform that inspires, informs, and fosters a thriving community in this transformative field.
Our team shares a passion for psychedelic medicine and we all have a different story on how we ended up here. We want to share those stories and highlight the amazing people that help us do what we do.
Connect with our team to explore how we can collaborate and unlock the potential of psychedelic medicine together, fostering growth and innovation in this dynamic industry.
NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Vancouver, British Columbia–(Newsfile Corp. – June 14, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FSE: 6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce that Robert Tessarolo, President and Chief Executive Officer, will participate in a virtual presentation at the upcoming H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17, 2021.
Figure 1: NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
To view an enhanced version of Figure 1, please visit:
The Company’s presentation will be available on-demand at the start of the conference.
For more information regarding the conference or to schedule a one-on-one meeting with management, please contact KCSA Strategic Communications at NeonMind@KCSA.com or your H.C. Wainwright representatives directly.
About NeonMind Biosciences Inc.
NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.
NeonMind’s consumer division currently sells NeonMind-branded coffee products in Canada through NeonMind’s direct to consumer e-commerce platform, and it has plans to launch dietary supplements in the United States this quarter.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”,”estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.
At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.